

TEXT
102770

102274 SEQ

Access DB#

SEARCH REQUEST FORM

Scientific and Technical Information Center

CRFE

Requester's Full Name: Bao Thuy Nguyen Examiner #: 73403 Date: 8/25/03
Art Unit: 1641 Phone Number: 8-4243 Serial Number: 09845, 126
Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Biopolymer
Inventors (please provide full names): Jackowski et al

Earliest Priority Filing Date: 4/30/01

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

please search SEQ ID NO. 1 specifically
residues 2-12.

please also search pending database
of inventor.

Thank You.

LS

1-11 ~~over~~

61
60

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>Hamby</u>	NA Sequence (#) _____	STN <u>137</u>
Searcher Phone #: _____	AA Sequence (#) <u>1</u>	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>8/28</u>	Bibliographic _____	Dr. Link _____
Date Completed: <u>8/28</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>SEQ 10/5/03</u>	Fulltext _____	Sequence Systems <u>02</u>
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: <u>SEQ 10/5/03</u>	Other _____	Other (specify) _____



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 102274

TO: Bao-thuy Nguyen
Location: CM1/7E05
Art Unit : 1641
Friday, August 29, 2003

Case Serial Number: 09845726

From : Susan Hanley
Location: Biotech-Chem Library
CM1 6B05
Phone: 305-4053

susan.hanley@uspto.gov

Search Notes

=> d his

(FILE 'HOME' ENTERED AT 17:40:20 ON 29 AUG 2003)

FILE 'CAPLUS' ENTERED AT 17:40:28 ON 29 AUG 2003

L1 153 S JACKOWSKI G?/AU
 L2 35 S STANTON E?/AU
 L3 48 S THATCHER B?/AU
 L4 31 S YANTHA J?/AU
 L5 3032 S MARSHALL J?/AU
 L6 3170 S L1-5
 L7 58 S L6 AND BIOPOLYMER
 L8 89 S L6 AND MOLECULAR WEIGHT
 L9 29 S L7 AND L8 ← 29 cites
 SELECT RN L9 1-29

FILE 'REGISTRY' ENTERED AT 17:42:57 ON 29 AUG 2003

L10 29 S E1-29 29 cpds for L9 cites

FILE 'CAPLUS' ENTERED AT 17:43:25 ON 29 AUG 2003

L11 29 S L10 AND L9 29 cites & 29 cpds displayed

=> d ibib abs hitstr 1-29

L11 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:849935 CAPLUS

DOCUMENT NUMBER: 137:348846

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons

INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy

PATENT ASSIGNEE(S): Syn.X Pharma, Inc., Can.

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088747	A2	20021107	WO 2002-CA633	20020429
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003013845	A1	20030116	US 2001-846351	20010430

PRIORITY APPLN. INFO.: US 2001-846351 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or the absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

IT 473553-05-8

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(biopolymer marker indicative of disease state having a mol. wt. of 1845 daltons)

RN 473553-05-8 CAPLUS


CN L-Arginine, L-arginyl-L-asparaginylglycyl-L-phenylalanyl-L-lysyl-L-seryl-L-histidyl-L-alanyl-L-leucyl-L-glutaminyll-L-leucyl-L-asparaginyl-L-asparaginyl-L-arginyl-L-glutaminyll-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 2-A



PAGE 3-A



PAGE 4-A



L11 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:849925 CAPLUS
 DOCUMENT NUMBER: 137:348845
 TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons
 INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
 PATENT ASSIGNEE(S): Syn.X Pharma, Inc., Can.
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

Same

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088731	A2	20021107	WO 2002-CA632	20020429
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003004307 A1 20030102 US 2001-845731 20010430

PRIORITY APPLN. INFO.: US 2001-845731 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-light detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

IT 473553-28-5

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(biopolymer marker indicative of disease state having a mol. wt. of 1211 daltons)

RN 473553-28-5 CAPLUS


CN L-Leucine, L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



ACCESSION NUMBER: 2002:849924 CAPLUS
DOCUMENT NUMBER: 137:348844
TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1690 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Vrees, Tammy; Yantha, Jason; Marshall, John
PATENT ASSIGNEE(S): Syn.X Pharma, Inc., Can.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

same

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088727	A2	20021107	WO 2002-CA617	20020429
WO 2002088727	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002169278	A1	20021114	US 2001-845730	20010430
US 6593298	B2	20030715		

PRIORITY APPLN. INFO.:

US 2001-845730 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

IT 473552-58-8


RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(biopolymer marker indicative of disease state having a mol. wt. of 1690 daltons)

RN 473552-58-8 CAPLUS


CN L-Leucine, L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:849923 CAPLUS

DOCUMENT NUMBER: 137:348791

TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1406 daltons

INVENTOR(S): Jackowski, George; Thatcher, Brad; Vrees, Tammy; Yantha, Jason; Marshall, John

PATENT ASSIGNEE(S): Syn.X Pharma, Inc., Can.

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088723	A2	20021107	WO 2002-CA611	20020426
WO 2002088723	A3	20030103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003040602 A1 20030227 US 2001-846347 20010430

PRIORITY APPLN. INFO.: US 2001-846347 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

IT 263562-85-2

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(biopolymer marker indicative of disease state having a mol. wt. of 1406 daltons)

RN 263562-85-2 CAPLUS


CN L-Lysine, L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L-.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



DOCUMENT NUMBER: 137:348843
 TITLE: Biopolymer marker indicative of disease state having a molecular weight of 2056 daltons
 INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy *same*
 PATENT ASSIGNEE(S): Syn.X Pharma, Inc., Can.
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088717	A2	20021107	WO 2002-CA578	20020425
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-845736 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.


IT 112805-24-0, Complement C3f (human)
 RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (biopolymer marker indicative of disease state having a mol. wt. of 2056 daltons)

RN 112805-24-0 CAPLUS


CN Complement C3f (human) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B



L11 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:849921 CAPLUS
 DOCUMENT NUMBER: 137:348842
 TITLE: Polymer marker indicative of disease state having a

INVENTOR(S): molecular weight of 1518 daltons. *Sank*
 Jackowski, George; Thatcher, Brad;
 Marshall, John; Yantha, Jason;
 Vrees, Tammy
 PATENT ASSIGNEE(S): Syn.X Pharma, Inc., Can.
 SOURCE: PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088716	A2	20021107	WO 2002-CA577	20020425
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-845765 A 20010430


AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

IT 25422-31-5, Fibrinopeptide A (human)
 RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (polymer marker indicative of disease state having a mol. wt. of 1518 daltons)



RN 25422-31-5 CAPLUS
 CN Fibrinopeptide A (human) (7CI, 8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B



L11 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:833556 CAPLUS

DOCUMENT NUMBER: 137:334916

TITLE: Alpha fibrinogen biopolymer marker indicative of myocardial infarction having a molecular weight of 1020 daltons

INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

US 2002161188	A1	20021031	US 2001-846350	20010430
US 6599877	B2	20030729		
WO 2002088728	A2	20021107	WO 2002-CA619	20020429
WO 2002088728	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846350 A 20010430


AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence DFLAEGGGVR and characterized as a .alpha. fibrinogen having a mol. wt . of 1020 daltons was found. This marker is indicative of myocardial infarction.


IT 59001-25-1, 7-16-Fibrinopeptide A (human)
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (alpha fibrinogen biopolymer marker of 1020 daltons indicative of myocardial infarction)

RN 59001-25-1 CAPLUS
 CN 7-16-Fibrinopeptide A (human) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L11 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:833555 CAPLUS

DOCUMENT NUMBER: 137:334915

TITLE: Apolipoprotein CIII biopolymer marker indicative of Type II diabetes having a molecular weight of 1097 daltons

INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161187	A1	20021031	US 2001-846352	20010430
WO 2002088743	A2	20021107	WO 2002-CA618	20020429
WO 2002088743	A3	20030103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846352 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of **biopolymers** which are verifiable within a particular sample. The cohort of **biopolymers** verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said **biopolymer**. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence PEVRPTSAVAA and characterized as a apolipoprotein CIII having a mol. wt . of 1097 daltons was found. This marker is indicative of Type II diabetes.

IT 473550-31-1

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(apolipoprotein CIII biopolymer marker of 1097 daltons
indicative of Type II diabetes)

RN 473550-31-1 CAPLUS


CN L-Alanine, L-prolyl-L-.alpha.-glutamyl-L-valyl-L-arginyl-L-prolyl-L-
threonyl-L-seryl-L-alanyl-L-valyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:833554 CAPLUS

DOCUMENT NUMBER: 137:334914

TITLE: Complement C3f biopolymer marker indicative
of myocardial infarction and congestive heart failure
having a molecular weight of 1449
daltons

INVENTOR(S): Jackowski, George; Thatcher, Brad;
Marshall, John; Yantha, Jason;
Vrees, Tammy

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161186	A1	20021031	US 2001-846349	20010430
US 6602855	B2	20030805		
WO 2002088726	A2	20021107	WO 2002-CA615	20020426
WO 2002088726	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846349 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence THRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1449 daltons was found. This marker is indicative of myocardial infarction, intracerebral hemorrhage, or congestive heart failure.

IT 112821-21-3, Complement C3f

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (complement C3f biopolymer marker of 1449 daltons indicative of myocardial infarction and congestive heart failure)

RN 112821-21-3 CAPLUS

CN Complement C3f (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 473549-42-7


RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (complement C3f biopolymer marker of 1449 daltons indicative of myocardial infarction and congestive heart failure)

RN 473549-42-7 CAPLUS


CN L-Leucine, L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:833553 CAPLUS
 DOCUMENT NUMBER: 137:334913
 TITLE: Alpha fibrinogen biopolymer marker
 indicative of renal failure having a molecular
 weight of 1206 daltons
 INVENTOR(S): Jackowski, George; Thatcher, Brad; *same*
 Marshall, John; Yantha, Jason;
 Vrees, Tammy
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161185	A1	20021031	US 2001-845725	20010430
WO 2002088721	A2	20021107	WO 2002-CA609	20020426
WO 2002088721	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.: US 2001-845725 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence EGDFLAEGGGVR and characterized as a .alpha. fibrinogen having a mol. wt


. of 1206 daltons was found. This marker is indicative of renal failure.
 IT 59001-24-0, 5-16-Fibrinopeptide A (human)
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
 USES (Uses)
 (alpha fibrinogen biopolymer marker of 1206 daltons indicative of renal failure)
 RN 59001-24-0 CAPLUS
 CN 5-16-Fibrinopeptide A (human) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:833552 CAPLUS
 DOCUMENT NUMBER: 137:334912
 TITLE: Complement C3f biopolymer marker indicative of myocardial infarction and congestive heart failure having a molecular weight of 1348 daltons
 INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 11 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161184	A1	20021031	US 2001-845715	20010430
WO 2002088720	A2	20021107	WO 2002-CA608	20020426

WO 2002088720 A3 20030206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845715 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence HRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1348 daltons was found. This marker is indicative of myocardial infarction, intracerebral hemorrhage, or congestive heart failure.

IT 112821-21-3, Complement C3f

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(complement C3f biopolymer marker of 1348 daltons indicative of myocardial infarction and congestive heart failure)

RN 112821-21-3 CAPLUS

CN Complement C3f (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 473546-75-7


RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(complement C3f biopolymer marker of 1348 daltons indicative of myocardial infarction and congestive heart failure)

RN 473546-75-7 CAPLUS


CN L-Leucine, L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:833551 CAPLUS

DOCUMENT NUMBER: 137:334911

TITLE: Apolipoprotein E biopolymer marker
indicative of insulin resistance having a
molecular weight of 2267 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; *same*
Marshall, John; Yantha, Jason;
Vrees, Tammy

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161183	A1	20021031	US 2001-846348	20010430
WO 2002088745	A2	20021107	WO 2002-CA624	20020429
WO 2002088745	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846348 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence TVGSLAQPLQERAQAWGERL and characterized as a apolipoprotein E having a mol. wt

. of 2267 daltons was found. This marker is indicative of insulin resistance.

IT 473546-72-4

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(apolipoprotein E biopolymer marker indicative of insulin resistance having a mol. wt. of 2267 daltons)

RN 473546-72-4 CAPLUS


CN L-Leucine, L-threonyl-L-valylglycyl-L-seryl-L-leucyl-L-alanylglycyl-L-glutamyl-L-prolyl-L-leucyl-L-glutamyl-L-.alpha.-glutamyl-L-arginyl-L-alanyl-L-glutamyl-L-alanyl-L-tryptophylglycyl-L-.alpha.-glutamyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 2-B



PAGE 2-C



IT 9004-10-8, Insulin, biological studies
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (resistance; apolipoprotein E biopolymer marker indicative of insulin resistance having a mol. wt. of 2267 daltons)
 RN 9004-10-8 CAPLUS
 CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L11 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:833550 CAPLUS
 DOCUMENT NUMBER: 137:334910
 TITLE: Complement C3f biopolymer marker indicative of myocardial infarction and congestive heart failure having a molecular weight of 1865 daltons
 INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy) same
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2002161182	A1	20021031	US 2001-846345	20010430
WO 2002088174	A2	20021107	WO 2002-CA622	20020429
WO 2002088174	A3	20030116		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846345 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence SSKITHRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1865 daltons was found. This marker is indicative of myocardial infarction, intracerebral hemorrhage, Type II diabetes, or congestive heart failure.

IT 112821-21-3, Complement C3f
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (complement C3f biopolymer marker of 1865 daltons indicative of myocardial infarction and congestive heart failure)

RN 112821-21-3 CAPLUS
 CN Complement C3f (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 473546-71-3
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (complement C3f biopolymer marker of 1865 daltons indicative of myocardial infarction and congestive heart failure)


RN 473546-71-3 CAPLUS
 CN L-Leucine, L-seryl-L-seryl-L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:833549 CAPLUS
 DOCUMENT NUMBER: 137:334909
 TITLE: Complement C3f biopolymer marker indicative
 of myocardial infarction and congestive heart failure
 having a molecular weight of 2021
 daltons
 INVENTOR(S): Jackowski, George; Thatcher, Brad;
 Marshall, John; Yantha, Jason; *same*
 Vrees, Tammy
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

US 2002161181	A1	20021031	US 2001-846344	20010430
WO 2002088711	A2	20021107	WO 2002-CA627	20020429
WO 2002088711	A3	20030116		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846344 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence SSKITHRIHWESASLLR and characterized as a complement C3f fragment having a mol. wt. of 2021 daltons was found. This marker is indicative of myocardial infarction, Type II diabetes, or congestive heart failure.

IT 112821-21-3, Complement C3f
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (complement C3f biopolymer marker of 2021 daltons indicative of myocardial infarction and congestive heart failure)

RN 112821-21-3 CAPLUS
 CN Complement C3f (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 112805-24-0, Complement C3f (human)
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (complement C3f biopolymer marker of 2021 daltons indicative of myocardial infarction and congestive heart failure)


RN 112805-24-0 CAPLUS
 CN Complement C3f (human) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B



L11 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:833548 CAPLUS
 DOCUMENT NUMBER: 137:334908
 TITLE: Complement C4A biopolymer marker indicative

of myocardial infarction and congestive heart failure
having a molecular weight of 1896
daltons

INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy *gane*

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161180	A1	20021031	US 2001-846343	20010430
WO 2002088724	A2	20021107	WO 2002-CA612	20020426
WO 2002088724	A3	20030103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846343 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence NGFKSHALQLNNRQIR and characterized as a complement C4A fragment having a mol. wt. of 1896 daltons was found. This marker is indicative of myocardial infarction, Type II diabetes, and congestive heart failure.

IT 80295-48-3, Complement C4
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(C4A; complement C4A biopolymer marker of 1896 daltons indicative of myocardial infarction and congestive heart failure)

RN 80295-48-3 CAPLUS

CN Complement C4 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 473546-69-9
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(complement C4A biopolymer marker of 1896 daltons indicative of myocardial infarction and congestive heart failure)

RN 473546-69-9 CAPLUS


CN L-Arginine, L-asparaginylglycyl-L-phenylalanyl-L-lysyl-L-seryl-L-histidyl-L-alanyl-L-leucyl-L-glutaminy-L-leucyl-L-asparaginy-L-asparaginy-L-arginyl-L-glutaminy-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 3-A



PAGE 4-A



L11 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:833547 CAPLUS

DOCUMENT NUMBER: 137:334907

TITLE: Alpha fibrinogen biopolymer marker
indicative of renal failure or intracerebral
hemorrhage having a molecular weight
of 1465 daltons

INVENTOR(S): Jackowski, George; Thatcher, Brad;
Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161179	A1	20021031	US 2001-845719	20010430
WO 2002088715	A2	20021107	WO 2002-CA576	20020425
WO 2002088715	A3	20030116		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845719 A 20010430

AB The instant invention involves the use of a combination of preparatory
steps in conjunction with mass spectroscopy and time-of-flight detection
procedures to maximize the diversity of biopolymers which are
verifiable within a particular sample. The cohort of biopolymers

verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence DSGEGFLAEGGGVR and characterized as a .alpha. fibrinogen having a mol. wt . of 1465 daltons was found. This marker is indicative of renal failure or intracerebral hemorrhage.

IT 107012-96-4, 2-16-Fibrinopeptide A (human)

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses).


(alpha fibrinogen biopolymer marker of 1465 daltons
indicative of renal failure or intracerebral hemorrhage)

RN 107012-96-4 CAPLUS


CN 2-16-Fibrinopeptide A (human) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



L11 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:833546 CAPLUS
 DOCUMENT NUMBER: 137:334906
 TITLE: Serum albumin biopolymer marker indicative
 of insulin resistance having a molecular
 weight of 2937 daltons
 INVENTOR(S): Jackowski, George; Thatcher, Brad;
 Marshall, John; Yantha, Jason;
 Vrees, Tammy
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161177	A1	20021031	US 2001-846329	20010430
WO 2002088742	A2	20021107	WO 2002-CA613	20020426
WO 2002088742	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846329 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence DAHKSEVAHRFKDLGEENFKALVLIA and characterized as a serum albumin having a mol. wt. of 2937 daltons was found. This marker is indicative of insulin resistance.

IT 9004-10-8, Insulin, biological studies
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (resistance; serum albumin biopolymer marker of 2937 daltons indicative of insulin resistance)

RN 9004-10-8 CAPLUS

CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 473546-58-6

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(serum albumin biopolymer marker of 2937 daltons indicative of insulin resistance)

RN 473546-58-6 CAPLUS


CN L-Alanine, L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L-.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-L-lysyl-L-.alpha.-aspartyl-L-leucylglycyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-asparaginyl-L-phenylalanyl-L-lysyl-L-alanyl-L-leucyl-L-valyl-L-leucyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A





PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 2-C

Et

L11 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:833503 CAPLUS
 DOCUMENT NUMBER: 137:334905
 TITLE: Serum albumin biopolymer marker indicative
 of renal failure having a molecular
 weight of 1521 daltons
 INVENTOR(S): Jackowski, George; Thatcher, Brad;
 Marshall, John; Yantha, Jason;
 Vrees, Tammy
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160958	A1	20021031	US 2001-845764	20010430
WO 2002088713	A2	20021107	WO 2002-CA631	20020429
WO 2002088713	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845764 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence DAHKSEVAHRFKD and characterized as a serum albumin having a mol. wt. of 1521 daltons was found. This marker is indicative of renal failure.

IT 473552-37-3

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(serum albumin biopolymer marker of 1521 daltons indicative of renal failure)

RN 473552-37-3 CAPLUS


CN L-Aspartic acid; L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L-.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 474276-98-7

RL: PRP (Properties)


(unclaimed sequence; serum albumin biopolymer marker
indicative of renal failure having a mol. wt. of
1521 daltons)


RN 474276-98-7 CAPLUS

CN L-Leucine, L-arginyl-L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-
seryl-L-.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-
phenylalanyl-L-lysyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160533	A1	20021031	US 2001-846779	20010430
WO 2002088730	A2	20021107	WO 2002-CA630	20020429
WO 2002088730	A3	20021227		
WO 2002088730	C1	20030320		

W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,	TM
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,	
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,	
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,	
	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TN, TR, TT, TZ,	
RW:	UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,	TM
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZM, ZW, AT, BE, CH,	
	CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,	
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	

PRIORITY APPLN. INFO.: US 2001-846779 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or

absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence PNHFRPAGLPEKY and characterized as a serum amyloid A having a mol. wt.

of 1525 daltons was found. This marker is indicative of myocardial infarction.

IT 331450-30-7

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(serum amyloid A biopolymer marker of 1525 daltons indicative of myocardial infarction)

RN 331450-30-7 CAPLUS


CN L-Tyrosine, L-prolyl-L-asparaginyl-L-histidyl-L-phenylalanyl-L-arginyl-L-prolyl-L-alanylglycyl-L-leucyl-L-prolyl-L-.alpha.-glutamyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:833429 CAPLUS

DOCUMENT NUMBER: 137:334903

TITLE: Complement C3f biopolymer marker indicative of Type II diabetes having a molecular weight of 1998 daltons

INVENTOR(S): Jackowski, George; Thatcher, Brad;

PATENT ASSIGNEE(S): Marshall, John; Yantha, Jason;
 SOURCE: Vrees, Tammy
 Can.
 U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160532	A1	20021031	US 2001-846346	20010430
WO 2002088707	A2	20021107	WO 2002-CA616	20020429

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846346 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence SSKITHRIHWESASLLR and characterized as a complement C3f fragment having a mol. wt. of 1998 daltons was found. This marker is indicative of Type II diabetes.

IT 112821-21-3, Complement C3f
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (complement C3f biopolymer marker of 1998 daltons indicative of type II diabetes)

RN 112821-21-3 CAPLUS
 CN Complement C3f (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 112805-24-0, Complement C3f (human)
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (complement C3f biopolymer marker of 1998 daltons indicative of type II diabetes)


RN 112805-24-0 CAPLUS
 CN Complement C3f (human) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B



L11 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:833428 CAPLUS
 DOCUMENT NUMBER: 137:333522
 TITLE: Biopolymer marker indicative of disease

state having a molecular weight of
2753 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad;
Marshall, John; Yantha, Jason;
Vrees, Tammy
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160531	A1	20021031	US 2001-846328	20010430
WO 2002088710	A2	20021107	WO 2002-CA626	20020429
WO 2002088710	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846328 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

IT 98420-25-8


RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(biopolymer marker indicative of disease state having a mol. wt. of 2753 daltons)

RN 98420-25-8 CAPLUS


CN L-Leucine, L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L-.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-L-lysyl-L-.alpha.-aspartyl-L-leucylglycyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-asparaginy-L-phenylalanyl-L-lysyl-L-alanyl-L-leucyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 1-C



PAGE 2-C



IT 9004-10-8, Insulin, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (resistance; biopolymer marker indicative of disease state
 having a mol. wt. of 2753 daltons)
 RN 9004-10-8 CAPLUS
 CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L11 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:833426 CAPLUS

DOCUMENT NUMBER: 137:334902

TITLE: Complement C3f biopolymer marker indicative of myocardial infarction or congestive heart failure having a molecular weight of 1562 daltons

INVENTOR(S): Jackowski, George; Thatcher, Brad; Vrees, Tammy; Yantha, Jason; Marshall, John

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160529	A1	20021031	US 2001-845738	20010430
WO 2002088729	A2	20021107	WO 2002-CA629	20020429
WO 2002088729	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845738 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence ITHRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1562 daltons was found. This marker is indicative of myocardial infarction or congestive heart failure.

IT 112821-21-3, Complement C3f

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (complement C3f biopolymer marker of 1562 daltons indicative of myocardial infarction or congestive heart failure)

RN 112821-21-3 CAPLUS

CN Complement C3f (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 473552-36-2

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(complement C3f biopolymer marker of 1562 daltons indicative of myocardial infarction or congestive heart failure)


RN 473552-36-2 CAPLUS

CN L-Leucine, L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-


histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:833425 CAPLUS
 DOCUMENT NUMBER: 137:334901
 TITLE: Alpha fibrinogen biopolymer marker
 indicative of myocardial infarction or renal failure
 having a molecular weight of 1350
 daltons
 INVENTOR(S): Jackowski, George; Thatcher, Brad;
 Marshall, John; Yantha, Jason;
 Vrees, Tammy
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

US 2002160528	A1	20021031	US 2001-845729	20010430
WO 2002088722	A2	20021107	WO 2002-CA610	20020426
WO 2002088722	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845729 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence SESDFLAEGGGVR and characterized as a .alpha. fibrinogen having a mol. wt . of 1350 daltons was found. This marker is indicative of myocardial infarction or renal failure.

IT 473552-35-1

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(alpha fibrinogen biopolymer marker of 1350 daltons indicative of myocardial infarction or renal failure)

RN 473552-35-1 CAPLUS


CN L-Arginine, L-seryl-L-.alpha.-glutamyl-L-seryl-L-.alpha.-aspartyl-L-phenylalanyl-L-leucyl-L-alanyl-L-.alpha.-glutamylglycylglycylglycyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:833402 CAPLUS
 DOCUMENT NUMBER: 137:334900
 TITLE: Complement C3f biopolymer marker indicative
 of myocardial infarction and congestive heart failure
 having a molecular weight of 1777
 daltons
 INVENTOR(S): Jackowski, George; Thatcher, Brad;
 Marshall, John; Yantha, Jason;
 Vrees, Tammy
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160434	A1	20021031	US 2001-845735	20010430
WO 2002088712	A2	20021107	WO 2002-CA628	20020429

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845735 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence SKITHRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1777 daltons was found. This marker is indicative of myocardial infarction, intracerebral hemorrhage, Type II diabetes, or congestive heart failure.

IT 112821-21-3, Complement C3f
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic

use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(complement C3f biopolymer marker of 1777 daltons indicative
of myocardial infarction and congestive heart failure)

RN 112821-21-3 CAPLUS

CN Complement C3f (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 473546-15-5

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
USES (Uses)


(complement C3f biopolymer marker of 1777 daltons indicative
of myocardial infarction and congestive heart failure)


RN 473546-15-5 CAPLUS

CN L-Leucine, L-seryl-L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-
isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-
seryl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160423	A1	20021031	US 2001-846780	20010430
WO 2002088718	A2	20021107	WO 2002-CA579	20020425
WO 2002088718	A3	20021227		

W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	
	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,	
RW:	UA,	UG,	UZ,	VN,	YU,	ZA,	ZM,	ZW,	AM,	AZ,	BY,	KG,	KZ,	MD,	RU,	TJ,	TM
	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	CH,	
	CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	
	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG	

PRIORITY APPLN. INFO.: US 2001-846780 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the

disease specific marker identified by the sequence ADSGEGDFLAEGGGVR and characterized as a .alpha. fibrinogen having a mol. wt . of 1536 daltons was found. This marker is indicative of myocardial infarction.

IT 25422-31-5, Fibrinopeptide A (human)

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(alpha fibrinogen biopolymer marker of 1536 daltons indicative of myocardial infarction)

RN 25422-31-5 CAPLUS


CN Fibrinopeptide A (human) (7CI, 8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





PAGE 2-B



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160422	A1	20021031	US 2001-846342	20010430
WO 2002088708	A2	20021107	WO 2002-CA620	20020429

W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,	TM
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,	
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,	
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,	
	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,	
RW:	UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,	TM
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, IT, UG, ZM, ZW, AT, BE, CH,	
	CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,	
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	

PRIORITY APPLN. INFO.: US 2001-846342 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence GDFLAEGGGVR and characterized as a .alpha. fibrinogen having a mol. wt . of 1077 daltons was found. This marker is indicative of myocardial infarction.

Searched by Susan Hanley 305-4053

use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
USES (Uses)


(alpha fibrinogen biopolymer marker of 1077 daltons
indicative of myocardial infarction)

RN 473551-61-0 CAPLUS


CN L-Arginine, glycyL-L-.alpha.-aspartyl-L-phenylalanyl-L-leucyl-L-alanyl-L-
.alpha.-glutamylglycylglycylglycyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:833394 CAPLUS

DOCUMENT NUMBER: 137:334897

TITLE: Complement C3f biopolymer marker indicative
of congestive heart failure having a molecular
weight of 1793 daltons

INVENTOR(S): Jackowski, George; Thatcher, Brad;
Marshall, John; Yantha, Jason;
Vrees, Tammy

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160419	A1	20021031	US 2001-845739	20010430
WO 2002088725	A2	20021107	WO 2002-CA614	20020426
WO 2002088725	A3	20030103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845739 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence SKITHRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1793 daltons was found. This marker is indicative of congestive heart failure.

IT 112821-21-3, Complement C3f

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (complement C3f biopolymer marker of 1793 daltons indicative of congestive heart failure)

RN 112821-21-3 CAPLUS

CN Complement C3f (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 473546-15-5


RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (complement C3f biopolymer marker of 1793 daltons indicative of congestive heart failure)

RN 473546-15-5 CAPLUS


CN L-Leucine, L-seryl-L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:833393 CAPLUS
 DOCUMENT NUMBER: 137:334896
 TITLE: Biopolymer marker indicative of Syndrome X
 disease state having a molecular
 weight of 1949 daltons
 INVENTOR(S): Jackowski, George; Thatcher, Brad;
 Marshall, John; Yantha, Jason;
 Vrees, Tammy
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 9 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160418	A1	20021031	US 2001-845727	20010430
WO 2002088746	A2	20021107	WO 2002-CA625	20020429
WO 2002088746	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845727 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the

presence and/or the absence of said **biopolymer**. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence DAHKSEVAHRFKDLGEE and characterized as a serum albumin having a mol. wt. of 1949 daltons was found. This marker is indicative of Syndrome X related diseases.

IT 473546-14-4

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(serum albumin **biopolymer** marker indicative of Syndrome X diseases having mol. wt. of 1949 daltons)

RN 473546-14-4 CAPLUS


CN L-Glutamic acid, L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L-.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-L-lysyl-L-.alpha.-aspartyl-L-leucylglycyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A



PAGE 1-B



PAGE 2-A



L11 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2002:833392 CAPLUS
 DOCUMENT NUMBER: 137:334895
 TITLE: Biopolymer marker indicative of disease state having a molecular weight of 1424 daltons
 INVENTOR(S): Jackowski, George; Stanton, Eric B.; Thatcher, Brad; Vrees, Tammy; Yantha, Jason; Marshall, John
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160417	A1	20021031	US 2001-845726	20010430
WO 2002088719	A2	20021107	WO 2002-CA593	20020426
WO 2002088719	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845726 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

IT 263562-87-4

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)


(biopolymer marker indicative of disease state having a mol. wt. of 1424 daltons)

RN 263562-87-4 CAPLUS

CN L-Lysine, L-alanyl-L-histidyl-L-lysyl-L-seryl-L-.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

